Immunogen Inc

IMGN

Market cap $8.72B

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.

IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).